170,103 research outputs found
Editorial for the special issue on 2d nanomaterials processing and integration in miniaturized devices
No full textInitially considered little more than a scientific curiosity, the family of 2D nanomaterials has become increasingly popular over the last decade [...]
Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group
No full textThe efficacy and safety of rufloxacin once daily was compared with that of ofloxacin b.i.d. for therapy of complicated cystitis and upper urinary tract infections. Eighty-three patients were randomly assigned to receive rufloxacin as a loading dose of 400 mg on the first day, followed by 200 mg s.i.d., and 80 received ofloxacin 300 mg b.i.d. Both agents were administered orally for a median duration of eight days. Bacterial elimination rates after treatment were 90% for rufloxacin and 81% for ofloxacin. Half of the treatment failures occurred in patients with infections caused by uropathogens that became either less sensitive or resistant to the quinolones being studied. At a two-week follow-up, recurrences had not occurred in any of the rufloxacin patients and had occurred in 17% of the ofloxacin patients. Minor adverse reactions were reported by 12 and 13 patients, respectively. Rufloxacin once daily is as effective as ofloxacin b.i.d. for the treatment of complicated cystitis and upper urinary tract infections
Free-Flying Robot Tested on ESA Parabolic Flights: Simulated Microgravity Tests and Simulator Validation
No full textDesign synthesis, in vitro biological evaluation and anti-biofilm activity of new beta-lactam and linezolid-like compound as potential antibacterial agents against Staphylococcus aureus infections in cystic fibrosis patients.
No full textProgetto interdisciplinare sulla progettazione e sintesi di nuovi antibiotici specifici per contrastare le infezioni da Staffilococco aureo in pazienti di fibrosi cistic
Carumonam's in-vitro activity against gram-negative bacteria and its stability to their beta-lactamases
No full textThe in vitro activity of the novel monobactam carumonam (RO17-2301) was evaluated on 311 gram-negative clinical isolates in comparison to aztreonam, cefotaxime, ceftazidime, cefotetan and ceftriaxone. Carumonam showed an antibacterial potency equal to or higher than any other reference compound; in particular it was the most effective against Proteus indole positive and Klebsiella sp. Its antipseudomonal activity was comparable to that of ceftazidime and it showed, together with aztreonam, the highest activity against the Citrobacter, Enterobacter and Escherichia coli isolates. The minimal inhibitory concentrations performed on permeability altered organisms indicated that carumonam has a penetration rate comparable to aztreonam and higher than cefotetan and ceftriaxone. Carumonam demonstrated excellent stability to chromosomal and plasmid-mediated beta-lactamases and that correlated with its antibacterial activity against the producing strains and inoculum size effect
Characterization of polycrystalline 3CB-SiC thin films for MEMS and pressure sensors application
No full text- …
